By: IPP Bureau
Last updated : January 14, 2026 7:09 am
The collaboration gives Axolabs access to Codexis’ innovative RNA manufacturing technology
Codexis, a leader in enzymatic solutions for scalable therapeutics manufacturing, has entered a strategic agreement with Axolabs, part of LGC Group, to evaluate Codexis’ ECO Synthesis Manufacturing Platform.
The collaboration gives Axolabs access to Codexis’ innovative RNA manufacturing technology, powered by enzymatic synthesis, with potential for future licensing and broader adoption of the platform.
"Part of our mission is to expand the reach of our ECO Synthesis Manufacturing Platform through collaborations with best-in-class CDMOs," said Alison Moore, President & CEO of Codexis. "Axolabs is an industry-leading CRDMO, and we are delighted to enter into this partnership with them to enable more efficient manufacturing of oligonucleotide therapeutics that address large markets."
Kathleen Campau, Senior Director of Operations for Axolabs, added: "This technology has the potential to be pivotal to how therapeutic oligonucleotides are manufactured at scale in the future, enabling more sustainable and cost-effective production. At Axolabs, we are committed to advancing the science behind therapeutic oligonucleotides, and this partnership builds on our long-standing legacy of technology leadership in the field."
The agreement underscores both companies’ dedication to driving innovation and expanding global access to high-quality oligonucleotide-based medicines.